Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

R. Nielsen; Henrik Wiggers; Mads Halbirk; H Bøtker; Jens Juul Holst; Ole Schmitz; Egon Randa Frandsen; S Nielsen; N Møller; Helene Nørrelund

doi:10.1055/s-0032-1304605

Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

R. Nielsen, Henrik Wiggers, Mads Halbirk, H Bøtker, Jens Juul Holst, Ole Schmitz, Egon Randa Frandsen, S Nielsen, N Møller, Helene Nørrelund

Department of Clinical Medicine

8 Citations (Scopus)

Abstract

Objectives: We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients. Methods: In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods. Results: 7 insulin resistant HF (EF 28%2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected. Conclusion: GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged. Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Original language	English
Journal	Experimental and Clinical Endocrinology and Diabetes
Volume	120
Issue number	5
Pages (from-to)	266-72
Number of pages	7
ISSN	0947-7349
DOIs	https://doi.org/10.1055/s-0032-1304605
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/s-0032-1304605

Cite this

@article{d31c5e62d8134a67ae50d6f92fdddd2f,

title = "Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients",

abstract = "Objectives: We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients. Methods: In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods. Results: 7 insulin resistant HF (EF 28%2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected. Conclusion: GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged. Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.",

author = "R. Nielsen and Henrik Wiggers and Mads Halbirk and H B{\o}tker and Holst, {Jens Juul} and Ole Schmitz and Frandsen, {Egon Randa} and S Nielsen and N M{\o}ller and Helene N{\o}rrelund",

note = "{\textcopyright} J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.",

year = "2012",

doi = "10.1055/s-0032-1304605",

language = "English",

volume = "120",

pages = "266--72",

journal = "Experimental and Clinical Endocrinology and Diabetes",

issn = "0947-7349",

publisher = "Johann Ambrosius Barth Verlag in Medizinverlage Heidelberg GmbH & Co. KG",

number = "5",

}

TY - JOUR

T1 - Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

AU - Nielsen, R.

AU - Wiggers, Henrik

AU - Halbirk, Mads

AU - Bøtker, H

AU - Holst, Jens Juul

AU - Schmitz, Ole

AU - Frandsen, Egon Randa

AU - Nielsen, S

AU - Møller, N

AU - Nørrelund, Helene

PY - 2012

Y1 - 2012

N2 - Objectives: We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients. Methods: In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods. Results: 7 insulin resistant HF (EF 28%2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected. Conclusion: GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged. Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

AB - Objectives: We studied the metabolic effects of 48-h GLP-1 treatment in insulin resistant heart failure patients. Methods: In a randomized placebo-controlled double-blinded cross-over study, 11 non-diabetic HF patients with IHD received 48-h GLP-1 and placebo-infusion. We applied OGTT, hyperinsulinemic clamp, indirect calorimetry, forearm, and tracer methods. Results: 7 insulin resistant HF (EF 28%2) patients completed the protocol. GLP-1 decreased plasma glucose levels (p=0.048) and improved glucose tolerance. 4 patients had hypoglycemic events during GLP-1 vs. none during placebo. GLP-1 treatment tended to increase whole body protein turnover (p=0.08) but did not cause muscle wasting. No significant changes in circulating levels of insulin, glucagon, free fatty acids or insulin sensitivity were detected. Conclusion: GLP-1 treatment decreased glucose levels and increased glucose tolerance in insulin resistant HF patients with IHD. Hypoglycemia was common and may limit the use of GLP-1 in these patients. Insulin sensitivity, lipid-, and protein metabolism remained unchanged. Data were collected at the examinational laboratories of Department of Endocrinology and Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

U2 - 10.1055/s-0032-1304605

DO - 10.1055/s-0032-1304605

M3 - Journal article

C2 - 22421983

SN - 0947-7349

VL - 120

SP - 266

EP - 272

JO - Experimental and Clinical Endocrinology and Diabetes

JF - Experimental and Clinical Endocrinology and Diabetes

IS - 5

ER -

Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this